Payment overview · 2025
General Payments
$243.94
14 reported records · 10 companies
Healthcare provider profile · identity verified
Gary Michael Early, DO
Allopathic & Osteopathic Physicians|Family Medicine · KIRKSVILLE, MO · NPI 1215913132
Verified facts
What the public records show
CMS Open Payments records show Gary Michael Early, DO received $243.94 in general payments during 2025 across 14 reported records.
Verona Pharma, Inc. accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $39.65 | 16.2% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $37.23 | 15.3% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $32.00 | 13.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $29.39 | 12.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.15 | 11.9% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $16.34 | 6.7% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $15.79 | 6.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.65 | 6.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.22 | 6.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.52 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $243.94 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $39.65 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $37.23 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $29.39 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 19 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 654 | 129 |
| Lisinopril | Lisinopril | 510 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 499 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 468 | 106 |
| Losartan Potassium | Losartan Potassium | 350 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 340 | 70 |
| Omeprazole | Omeprazole | 336 | 67 |
| Gabapentin | Gabapentin | 304 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 301 | 63 |
| Alprazolam | Alprazolam | 291 | 47 |
| Tramadol Hcl | Tramadol Hcl | 271 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 237 | 40 |
| Atenolol | Atenolol | 227 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 224 | 36 |
| Meloxicam | Meloxicam | 198 | 52 |
| Metformin Hcl | Metformin Hcl | 198 | 42 |
| Simvastatin | Simvastatin | 185 | 42 |
| Furosemide | Furosemide | 178 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 175 | 29 |
| Lorazepam | Lorazepam | 169 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 40 |
| Carvedilol | Carvedilol | 155 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 152 | 36 |
| Celecoxib | Celecoxib | 151 | 41 |
| Potassium Chloride | Potassium Chloride | 150 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 33 |
| Montelukast Sodium | Montelukast Sodium | 143 | 30 |
| Allopurinol | Allopurinol | 139 | 36 |
| Sertraline Hcl | Sertraline Hcl | 132 | 26 |
| Clonazepam | Clonazepam | 129 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 126 | 33 |
| Estradiol | Estradiol | 115 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 111 | 19 |
| Eliquis | Apixaban | 110 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 18 |
| Xarelto | Rivaroxaban | 80 | 13 |
| Diazepam | Diazepam | 77 | 15 |
| Azithromycin | Azithromycin | 76 | 58 |
| Metformin Hcl Er | Metformin Hcl | 76 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 74 | 19 |
| Glipizide | Glipizide | 72 | 17 |
| Donepezil Hcl | Donepezil Hcl | 71 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 71 | suppressed |
| Temazepam | Temazepam | 71 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 17 |
| Pregabalin | Pregabalin | 67 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 61 | suppressed |
| Finasteride | Finasteride | 61 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | suppressed |
| Spironolactone | Spironolactone | 60 | 12 |
| Glimepiride | Glimepiride | 57 | 13 |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Prednisone | Prednisone | 56 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Topiramate | Topiramate | 50 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 50 | 13 |
| Lansoprazole | Lansoprazole | 46 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Naproxen | Naproxen | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Ozempic | Semaglutide | 41 | suppressed |
| Torsemide | Torsemide | 41 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | suppressed |
| Roflumilast | Roflumilast | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 31 |
| Glipizide Er | Glipizide | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Famotidine | Famotidine | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 16 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 20 |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 11 |
| Amoxicillin | Amoxicillin | 24 | 15 |
| Bumetanide | Bumetanide | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 15 |
| Fluconazole | Fluconazole | 24 | 15 |
| Linzess | Linaclotide | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 22 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 12 |
| Proair Respiclick | Albuterol Sulfate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 18 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Oxycontin | Oxycodone Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.94 · 14 records | Verona Pharma, Inc. | ABRYSVO, AIRSUPRA, Cologuard Collection Kit, JOURNAVX, Ohtuvayre, Ozempic, PREVNAR 20, Prolastin-C Liquid, Rybelsus, Tymlos, YUPELRI, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error